Schultz LM (30) revealed that the 1-year cumulative recurrence rate of anti-CD19 CAR T-cell therapy in children and adolescent patients with B-ALL was as high as 37% (CD19 positive was 21%, CD19 negative was 16%). The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.